Welcome to our dedicated page for Lisata Therapeutics news (Ticker: LSTA), a resource for investors and traders seeking the latest updates and insights on Lisata Therapeutics stock.
Lisata Therapeutics, Inc. (Nasdaq: LSTA) is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for the treatment of advanced solid tumors and other major diseases. The company's flagship product candidate, LSTA1, is an investigational drug designed to enhance the penetration and targeting of co-administered or tethered anti-cancer drugs into solid tumors through a novel uptake pathway. This mechanism makes LSTA1 a promising adjunct to existing anti-cancer therapies, potentially improving their efficacy.
Lisata's research and development activities leverage its proprietary CendR Platform® Technology, which aims to provide better therapeutic outcomes for patients with challenging solid tumors. The company's core product, LSTA1, has demonstrated favorable safety, tolerability, and promising activity in clinical trials. Significant progress has been made in ongoing Phase 2a and 2b studies targeting a variety of solid tumor types.
Recent achievements for Lisata include:
- A complete response in a patient with metastatic gastroesophageal adenocarcinoma when LSTA1 was combined with standard-of-care treatments.
- The initiation of a Phase 2a study for newly diagnosed glioblastoma multiforme (GBM) across multiple sites in Estonia and Latvia.
- Receiving Orphan Drug Designation (ODD) from the FDA for glioblastoma multiforme and osteosarcoma.
- Securing a Fast Track designation from the FDA for LSTA1 in pancreatic cancer.
- Significant financial milestones achieved, including a reported cash runway extending into early 2026 to support ongoing development efforts.
Financially, Lisata reported operating expenses of $25.7 million for the twelve months ending December 31, 2023, a substantial reduction from $57.6 million in 2022. The company continues to prioritize efficient resource management, ensuring sustained progress in its clinical programs.
Lisata boasts strategic collaborations and commercial partnerships to expand its reach and impact. Its partnership with Qilu Pharmaceutical in Greater China aims to develop LSTA1 for metastatic pancreatic ductal adenocarcinoma (mPDAC). Additionally, the European Medicines Agency (EMA) granted a pediatric investigation plan waiver for LSTA1 in pancreatic cancer, facilitating streamlined regulatory approval processes.
Lisata Therapeutics continues to advance toward its goal of providing breakthrough treatments for patients with advanced solid tumors, positioning itself as a leader in the biopharmaceutical industry.
BASKING RIDGE, N.J., April 27, 2023 (GLOBE NEWSWIRE) -- Lisata Therapeutics, a clinical-stage pharmaceutical company, announced that CEO David J. Mazzo, PhD, will present at three upcoming conferences:
- LSX World Congress: May 3-4, 2023 in London. Dr. Mazzo's presentation will be on May 3 at 11:15 a.m. British Summer Time.
- Sidoti Micro-Cap Conference: May 10-11, 2023, virtual. Dr. Mazzo will present on May 10 at 10:00 a.m. Eastern Time.
- Bio€quity Europe 2023: May 14-16, 2023 in Dublin. Dr. Mazzo's presentation is set for May 15 at 1:41 p.m. Irish Standard Time.
Lisata develops innovative therapies for advanced solid tumors and is advancing its lead candidate, LSTA1, designed to enhance anti-cancer drug delivery while minimizing effects on normal tissues. The company is actively exploring treatment modalities for various solid tumors.
Lisata Therapeutics (Nasdaq: LSTA), a clinical-stage pharmaceutical company, has secured $2.2 million in non-dilutive funding through New Jersey's Technology Business Tax Certificate Transfer Program. This funding allows Lisata to convert state net operating losses into working capital, which will enhance their clinical development initiatives. Over the past four years, Lisata has received nearly $18 million through this program. The company is focused on advancing its therapeutic candidate, LSTA1, designed to improve the delivery of anti-cancer drugs to solid tumors. LSTA1 has shown promising results in clinical trials, particularly for pancreatic cancer, and may enhance the efficacy of various cancer treatments while minimizing side effects on normal tissues.
Lisata Therapeutics, a clinical-stage pharmaceutical company focused on innovative therapies for advanced solid tumors, will participate in the Sequire Investor Summit from April 24-26, 2023, at La Concha Resort in San Juan, Puerto Rico. CEO David J. Mazzo will present a company overview on April 25 at 3:00 PM. The event aims to connect emerging companies with investors.
Lisata's lead investigational product, LSTA1, targets novel uptake pathways for anti-cancer drugs, enhancing their delivery to tumors while sparing normal tissues. It has shown favorable safety and activity in clinical trials for pancreatic cancer, and has potential for various treatment modalities, including immunotherapies. The company continues to gather data to support LSTA1's effectiveness against a range of solid tumors.
Lisata Therapeutics (LSTA) has initiated the iLSTA Trial, a pivotal study evaluating its investigational drug LSTA1 in combination with standard chemotherapy and immunotherapy for locally advanced pancreatic ductal adenocarcinoma (PDAC). Conducted in Australia, this trial aims to treat 30 patients and assess safety and pharmacodynamics. WARPNINE will manage the trial, providing funding and recruitment support, while Lisata supplies the drug and regulatory assistance. LSTA1 is designed to enhance drug delivery to tumors, potentially improving treatment outcomes for patients with this challenging cancer. Positive early results could signify a major breakthrough in pancreatic cancer therapy.
Lisata Therapeutics, Inc. (Nasdaq: LSTA) reported its 2022 financial results and a business update, highlighting significant clinical developments in its drug pipeline. The lead candidate, LSTA1, is advancing in global studies for solid tumors, showing promise in enhancing delivery of anti-cancer drugs. HONEDRA® is in pre-consultation for registration in Japan, while XOWNA® faces enrollment challenges due to COVID-19 impacts. Financially, the company saw a 26% decrease in R&D expenses for the year, totaling $13.1 million, and experienced net losses of $54.2 million. As of December 31, 2022, Lisata had $69.2 million in cash, projected to sustain operations through mid-2025.
Lisata Therapeutics, Inc. (Nasdaq: LSTA) announced it will report its financial results for Q4 and FY 2022 on March 30, 2023, post-market. The conference call will start at 4:30 p.m. ET, with a new registration process for participants. Lisata is a clinical-stage company focused on developing innovative therapies for advanced solid tumors. Its lead product, LSTA1, aims to enhance the delivery of anti-cancer drugs to tumors while sparing normal tissues, showing promising results in pancreatic cancer trials. Lisata continues to explore LSTA1 for various solid tumors, alongside its autologous CD34+ cell therapy technology.
Lisata Therapeutics (Nasdaq: LSTA) announced its participation in two major investor conferences. The first event is the 2023 BIO CEO & Investor Conference in New York, scheduled for February 6-9, 2023, where CEO David J. Mazzo will present on February 7. The second event is Biocom California’s 13th Annual Global Life Science Partnering & Investor Conference in La Jolla, taking place from February 28 to March 2, 2023, with President David S. Slack presenting on March 1. These conferences will include one-on-one investor meetings. Lisata focuses on innovative therapies for advanced tumors, with its lead candidate, LSTA1, showing promise in enhancing drug delivery for pancreatic cancer.
FAQ
What is the current stock price of Lisata Therapeutics (LSTA)?
What is the market cap of Lisata Therapeutics (LSTA)?
What is Lisata Therapeutics' primary focus?
What is LSTA1?
What recent achievement did Lisata announce regarding LSTA1?
What designations has LSTA1 received from regulatory authorities?
How is Lisata financially positioned?
What are some of Lisata's strategic partnerships?
Where is Lisata Therapeutics headquartered?
What are Lisata's future plans for LSTA1?
How does LSTA1 work?
What is the significance of the EMA pediatric waiver for LSTA1?
